PTC Therapeutics (PTCT) Q3 FY2023 earnings: revenue $197 million, down 9.5% on the year

PTC Therapeutics, Inc. (PTCT) reported revenue of $197 million for Q3 FY2023, the quarter ended 30 September 2023, down 9.5% on the same quarter a year earlier. Net income was -$133 million, and diluted earnings per share $-1.76. The figures are the company's own, from the 10-Q it filed with the SEC on 26 October 2023.

Revenue$197 milliondown 9.5%

Net income-$133 million

Diluted EPS$-1.76

QuarterQ3 FY2023ended 30 September 2023

The quarter, against the one before and a year earlier

Line	Q3 FY2023	Quarter before	A year earlier	Change on the year
Revenue	197	n/a	n/a	n/a
Research and development	164	n/a	n/a	n/a
Selling, general and administrative	80.9	n/a	n/a	n/a
Operating income	-118	n/a	n/a	n/a
Operating margin	-60.1%	n/a	n/a
Pre-tax income	-167	n/a	n/a	n/a
Income tax	-33.6	n/a	n/a	n/a
Net income	-133	n/a	n/a	n/a
Net margin	-67.6%	n/a	n/a
Diluted EPS	-$1.76	n/a	n/a	n/a

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

Line	Q3 FY2023	Quarter before	A year earlier	Change on the year
Operating cash flow	-14.5	n/a	n/a	n/a
Capital expenditure	6.4	n/a	n/a	n/a
Free cash flow	-20.9	n/a	n/a	n/a
Free cash flow margin	-10.6%	n/a	n/a
Cash from investing	-29.6	n/a	n/a	n/a
Cash from financing	3.4	n/a	n/a	n/a
Depreciation and amortisation	62.1	n/a	n/a	n/a
Share-based compensation	26.9	n/a	n/a	n/a
Diluted shares, weighted	75m	n/a	n/a	n/a
Shares outstanding at period end	75m	n/a	n/a	n/a

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

Line	Q3 FY2023	Quarter before	A year earlier	Change on the year
Shareholders' equity	-671	n/a	n/a	n/a
Debt	573	n/a	n/a	n/a
Operating lease liabilities	99.7	n/a	n/a	n/a
Finance lease liabilities	17.2	n/a	n/a	n/a
Other liabilities	1,241	n/a	n/a	n/a
Total liabilities and equity	1,260	n/a	n/a	n/a
Fixed assets	85.0	n/a	n/a	n/a
Goodwill	82.3	n/a	n/a	n/a
Intangible assets	423	n/a	n/a	n/a
Investments	130	n/a	n/a	n/a
Cash and equivalents	165	n/a	n/a	n/a
Receivables	166	n/a	n/a	n/a
Inventory	35.8	n/a	n/a	n/a
Other assets	173	n/a	n/a	n/a
Total assets	1,260	n/a	n/a	n/a

Questions

What was PTC Therapeutics' revenue in Q3 FY2023?

PTC Therapeutics (PTCT) reported revenue of $197 million for Q3 FY2023, the quarter ended 30 September 2023, down 9.5% on the same quarter a year earlier.

How much did PTC Therapeutics earn in Q3 FY2023?

Net loss for Q3 FY2023 was $133 million, and the diluted loss per share $1.76.

When did PTC Therapeutics report Q3 FY2023 results?

PTC Therapeutics filed its 10-Q for the quarter ended 30 September 2023 with the SEC on 26 October 2023.

Quarterly results, the last 12 quarters

	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026
Revenue	197	307	210	187	197	213	1,176	179	211	165	273	361
R&D	164	121	116	132	161	125	109	113	100	133	101	99.2
SG&A	80.9	76.3	73.3	69.5	73.5	84.7	81.0	85.3	84.0	96.9	86.2	80.6
Operating income	-118	5.8	-45.5	-40.2	-54.5	-162	970	-35.0	3.0	-71.3	45.0	149
Operating margin	-60%	2%	-22%	-22%	-28%	-76%	82%	-20%	1%	-43%	16%	41%
Pre-tax income	-167	-157	-84.7	-85.7	-98.0	-94.7	930	-71.1	-23.1	-139	-2.5	97.5
Tax rate	n/a	n/a	n/a	n/a	n/a	n/a	7%	n/a	n/a	n/a	n/a	14%
Net income	-133	-156	-91.6	-99.2	-107	-65.9	867	-64.8	15.9	-135	-2.8	83.5
Net margin	-68%	-51%	-44%	-53%	-54%	-31%	74%	-36%	8%	-82%	-1%	23%
Diluted EPS	-$1.76	-$2.06	-$1.20	-$1.29	-$1.39	-$0.85	$10.04	-$0.83	$0.20	-$1.67	-$0.03	$0.92
Operating cash flow	-14.5	-100	70.8	-71.5	-77.0	-30.0	870	-58.3	-66.3	-34.3	-59.0	129
Capital expenditure	6.4	5.6	9.6	n/a	0.5	3.8	1.7	1.3	3.4	2.4	1.2	2.2
Free cash flow	-20.9	-106	61.2	n/a	-77.5	-33.8	868	-59.6	-69.7	-36.6	-60.2	127
Shares outstanding	75m	76m	77m	77m	77m	78m	79m	79m	80m	81m	83m	83m
Filing	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS and diluted share count are from the company's results press release for that quarter, used where the release gives the same revenue and net income as the table. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-Q for the period ended 30 September 2023, filed 26 October 2023, accession 0001070081-23-000065: the filing on EDGAR. All of PTC Therapeutics, Inc.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install